Protherics PLC, the biopharmaceutical company focused on critical care and oncology (the “Company”), announces the grant of options over ordinary shares in the Company (“Ordinary Shares”), on 11 January 2006, to the following PDMR under the terms of the Protherics PLC 1998 Savings-Related Share Option Scheme. The options are exercisable at a price of 65 pence per Ordinary Share.
